Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company’s ...
"Our 12-month price target of $20.00 per share implies shares could appreciate nearly four-fold over the next twelve months. OCEA's valuation improvement prior to commercialization of its drug ...
Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation of equity analyst coverage by EF Hutton with a "Buy" ...
Ocean Biomedical's fundamental story is still uncertain, and the long-term trajectory is unclear. The company remains in the translational phase of development, with efforts focused on targeting the ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results